NEW YORK (GenomeWeb News) – Mayo Clinic is partnering with three US healthcare groups to study if prescribing heart medications based on a patient's genotype will improve outcomes in angioplasty patients, NorthShore University HealthSystem, one of the project partners, said today.

The Tailored Antiplatelet Therapy to Lessen Outcomes After Percutaneous Coronary Intervention (TAILOR-PCI) study seeks to find out if testing for a patient's genotype will help prevent heart attack, stroke, unstable angina, and cardiovascular death in patients who undergo angioplasty.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.